Results 1 to 10 of about 10,028,727 (294)
Efficacy and safety of novel oral anticoagulants versus vitamin K antagonists in the treatment of venous thromboembolism [PDF]
Bangladesh Journal of Pharmacology, 2018 The aim of this meta-analysis was to systematically evaluate the efficacy and safety of novel oral anticoagulants and vitamin K antagonists in the treatment of venous thromboembolism.
Maodi Xu +4 more
doaj +2 more sources
Nephrotic Syndrome Thromboprophylaxis With Direct Oral Anticoagulants or Vitamin K Antagonists [PDF]
Kidney International ReportsIntroduction: Nephrotic syndrome (NS) is a pathological state of the glomerular filtration barrier associated with an increased venous and arterial thrombotic risk.
Edouard Cubilier +9 more
doaj +2 more sources
Effects of oral anticoagulants on bone health (systematic literature review)
Bolʹ, Sustavy, Pozvonočnik, 2023 Background. Osteoporosis is actually today's problem, as it affects the quality and length of life, and increases the risk of fragility fractures, which leads to significant medical, social, and economic problems.
H.V. Mostbauer +4 more
doaj +1 more source
Oral anticoagulation in patients with atrial fibrillation and end-stage kidney disease [PDF]
Revista Portuguesa de Nefrologia e Hipertensão, 2022 Atrial fibrillation is highly prevalent in patients with end -stage kidney disease. For patients with atrial fibrillation but normal kidney function, the net clinical benefit of oral anticoagulation with vitamin K antagonists and non -vitamin K oral ...
Tânia B. Azevedo, Sofia Correia
doaj +1 more source
NEW ORAL ANTICOAGULANTS: FOCUS ON THE SAFETY
Рациональная фармакотерапия в кардиологии, 2015 Comparative analysis of oral anticoagulants (vitamin K antagonists and new drugs, including dabigatran, rivaroxaban and apixaban) is presented from the standpoint of safety.
D. A. Napalkov, A. A. Sokolova
doaj +3 more sources
Vitamin K Status of Patients Undergoing Hemodialysis: Insights from a Cross-Sectional Study
Applied Sciences, 2023 (1) Background: Vitamin K deficiency is a common feature of chronic kidney disease (CKD), leading to impaired bone quality and an increased risk of vascular calcifications.
Marcel Palamar +8 more
doaj +1 more source
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2023 Background Important disparities in the treatment and outcomes of women and men with atrial fibrillation (AF) are well recognized. Whether introduction of direct oral anticoagulants has reduced disparities in treatment is uncertain.
Kuan Ken Lee +14 more
doaj +1 more source
Frontiers in Pharmacology, 2023 Objectives: Our objective was to analyse effectiveness and safety of oral anticoagulants (OAC) for stroke prevention in non-valvular atrial fibrillation.Material and methods: Population-based cohort study including adults initiating oral anticoagulants ...
Maria Giner-Soriano +18 more
doaj +1 more source
Recanalization rate of proximal deep venous thrombosis related to therapeutic modality during six months follow-up [PDF]
Medicinski Glasnik, 2022 Aim To evaluate the efficacy (rate of recanalization) of therapy with novel oral anticoagulants (NOAC; rivaroxaban, apixaban) compared to conventional treatment (low molecular weight heparin - LMWH and vitamin K antagonist) in the treatment of deep vein ...
Alden Begić +6 more
doaj +1 more source
Prevention of thromboembolic complications in patients with atrial fibrillation and obesity
Annales Academiae Medicae Silesiensis, 2023 Atrial fibrillation (AF) is an arrhythmia that occurs in 1–2% of the population. Chronic oral anticoagulation is recommended in the group of patients with AF to prevent thromboembolic complications. Obesity is a factor contributing to the development and
Izabela Kolasa, Beata Średniawa
doaj +1 more source